Similarly, a molecular study on 97 liver cancers with biliary phenotype reported a higher recurrence rate of KRAS (20%) and IDH1/2 (20%) mutations in hepatitis-negative patients, compared to hepatitis-positive patients [43]. This evidence concerns the gene KRAS and hepatitis A virus infection.